Literature DB >> 16093823

Lung transplantation and interstitial lung disease.

Raed Alalawi1, Timothy Whelan, Ravinder S Bajwa, Tony N Hodges.   

Abstract

PURPOSE OF REVIEW: Interstitial lung disease includes a heterogeneous group of disorders that leads to respiratory insufficiency and death in a significant number of patients. Lung transplantation is a therapeutic option in select candidates. RECENT
FINDINGS: The indications, transplant procedure options, and outcomes continue to evolve. Various recipient comorbidities influence the choice of procedure in patients with interstitial lung disease. Single lung transplants are used as the procedure of choice and bilateral transplants are reserved for patients with suppurative lung disease and patients with pulmonary hypertension. Issues unique to patients with interstitial lung disease affect the morbidity, mortality and recurrence of the disease.
SUMMARY: Lung transplantation is an effective therapy for respiratory failure in interstitial lung disease with survival following transplant being similar to that achieved in transplant recipients with other diseases.

Entities:  

Mesh:

Year:  2005        PMID: 16093823     DOI: 10.1097/01.mcp.0000175520.41729.4e

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  3 in total

Review 1.  [Therapy for idiopathic interstitial pneumonias: steroids--and what else?].

Authors:  A Prasse; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2006-12       Impact factor: 0.743

2.  Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis.

Authors:  Adam Fang; Sean Studer; Steven M Kawut; Vivek N Ahya; James Lee; Keith Wille; Vibha Lama; Lorraine Ware; Jonathan Orens; Ann Weinacker; Scott M Palmer; Maria Crespo; David J Lederer; Clifford S Deutschman; Benjamin A Kohl; Scarlett Bellamy; Ejigayehu Demissie; Jason D Christie
Journal:  Chest       Date:  2010-09-23       Impact factor: 9.410

3.  [Pulmonary fibrosis].

Authors:  A Prasse; J U Holle; J Müller-Quernheim
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.